ThromboGenics pulls ocriplasmin BLA; to resubmit in April

ThromboGenics N.V. (Euronext:THR) withdrew a BLA for ocriplasmin to treat symptomatic vitreomacular adhesion (VMA) after receiving notice that FDA intended to grant the application a six-month Priorit...